



# Modern Paradigm Towards Potential Target Identification for Antiviral (SARS-nCoV-2) and Anticancer Lipopeptides: A Pharmacophore-Based Approach

Manisha Yadav and J. Satya Eswari \*

Department of Biotechnology, National Institute of Technology Raipur, Chhattisgarh, 492010, India

## Abstract

**Background:** Lipopeptides are potential microbial metabolites that are abandoned with broad spectrum biopharmaceutical properties ranging from antimicrobial, antiviral and anticancer, *etc.* Clinical studies are not much explored beyond the experimental methods to understand drug mechanisms on target proteins at the molecular level for large molecules. Due to the less available studies on potential target proteins of lipopeptide based drugs, their potential inhibitory role for more obvious treatment on disease have not been explored in the direction of lead optimization. However, Computational approaches need to be utilized to explore drug discovery aspects on lipopeptide based drugs, which are time saving and cost-effective techniques.

**Methods:** Here a ligand-based drug discovery approach is coupled with reverse pharmacophore-mapping for the prediction of potential targets for antiviral (SARS-nCoV-2) and anticancer lipopeptides. Web-based servers PharmMapper and Swiss Target Prediction are used for the identification of target proteins for lipopeptides surfactin and iturin produced by *Bacillus subtilis*.

**Results:** The studies have given the insight to treat the diseases with next-generation large molecule therapeutics. Results also indicate the affinity for Angiotensin-Converting Enzymes (ACE) and proteases as the potential viral targets for these categories of peptide therapeutics. A target protein for the Human Papilloma Virus (HPV) has also been mapped.

**Conclusion:** The work will further help in exploring computer-aided drug designing of novel compounds with greater efficiency where the structure of the target proteins and lead compounds are known.

*Avicenna J Med Biotech 2022; 14(1): 70-78*

**Keywords:** Antiviral agents, *Bacillus subtilis*, Drug discovery, Ligands, Lipopeptides, Peptide hydrolases

## Introduction

The focus of the current trends in computer-aided drug discovery is to understand the disease mechanism, and further target identification takes place. On the edge of personalized medicine, the system is based upon the molecular basis of fundamentals in drug designing<sup>1</sup>. The interplay mentioned above can be addressed by imparting the cheminformatics tools in high throughput format. Cancer is a life-threatening disease which is one of the severe health problem globally. The increasing drug resistance has urged for the search of novel anticancer agents<sup>2</sup>. However, steadily increasing drug resistance in the treatment of infectious disease posed a severe problem in antimicrobial therapy and necessitates continuing research on different classes of drug derivatives<sup>3</sup>.

Lipopeptides are known as anti-microbial, anti-tumor, anti-inflammatory, anti-hypertensive, anti-para-

sitic, and anti-cancer compounds<sup>4</sup>. The lipopeptides exhibit various biological activities due to the presence of lipid and peptide moiety. Moreover, numerous therapeutically important medicines like peptide therapeutics contain a heterocyclic nucleus. Lipopeptides are amphiphilic compounds of natural origin and found with various therapeutic properties. Surfactin and Iturin lipopeptides produced by *Bacillus subtilis* (*B. subtilis*) are reported with antiviral and anticancer properties<sup>5-8</sup>. The studies on lipopeptides have been explored for antiviral activities against Corona virus (SARS-nCoV-2)<sup>9</sup>. Large molecule therapeutics are found with higher target specificity as compared to small molecules and has the potential to inhibit target proteins from multiple sites figure 1. Hence exploring the drugs with higher selectivity help in subsiding side effects and non-specific cytotoxicity of small-molecule inhibitors in cancer

\* **Corresponding author:**  
J. Satya Eswari, Ph.D.,  
Department of Biotechnology,  
National Institute of Technology  
Raipur, Chhattisgarh, 492010,  
India  
**E-mail:**  
satyaeswarij.bt@nitrr.ac.in  
**Received:** 15 Mar 2021  
**Accepted:** 28 Jul 2021




Figure 1. Molecular docking interaction: cyclic peptide drug docked with target protein (electrostatic surface interaction). Ability of cyclic peptide to inhibit target from multiple sites.

treatment<sup>10,11</sup>.

The first and subsequent second wave of COVID-19 pandemic due to the outbreak of SARS-nCov-2 (South East Respiratory Syndrome-Novel Corona Virus-2) is concurring the world leading to the global emergency to seek potential treatment options. The current management of the disease through drug repurposing has been an efficient way to combat the corona virus infection. Various target proteins and potential drug options are being explored to defeat the viral pathogenicity<sup>12</sup>. Lipopeptides have been known as potential antiviral compounds and such therapeutic options are also being researched<sup>13,14</sup>. The need of the hour is to first map the viral targets with the available potential therapeutics in an order to understand their mechanism of action for the novel drug discovery and drug repurposing<sup>12,15</sup>. Such studies will facilitate to further accelerate the drug discovery pipeline to combat future pandemics through the discovery of next generation therapeutic options such as peptides and lipopeptides.

There is an urgent need to explore such a new class of drugs where the drug resistance is threatening the world with a slow pipeline of drugs instead of having fledged with increased knowledge and technology-driven facilities<sup>10</sup>. The struggle starts with the identification of potential targets for large molecule therapeutics<sup>16</sup>. Here a drug discovery approach is coupled with pharmacophore-based virtual screening for the effective prediction of potential targets for lipopeptides. The studies have not been explored in the direction of lead optimization of natural compounds to increase the target specificity of the drug. Though, target identification is the primary step towards novel drug discovery. *In silico* methods, facilitate the cost-effective ways for target identification and lead optimization in reduced time and chemical exposure<sup>7</sup>. Structure-based pharmacophore mapping is a useful technique when insufficient information on ligand molecule is available and therapeutic activity (induce or block) for a particular disease is experimentally proved. It is used to explore information about the receptor site. It gives more in-

depth insight for the receptor-ligand interaction at the molecular level<sup>17</sup>.

In view of the above mentioned facts, compounds derived from synthesis are directed towards the proteomic approach extensively for the identification of potential binding proteins. These techniques are based upon comparative studies on protein expression profiling concerning the presence and absence of a given molecule for a particular cell or tissue. Such methods are not much successful in the discovery of target proteins because these are time consuming and laborious<sup>18</sup>. In the case of large molecule natural compounds, the task is even more challenging to execute and incurs huge wastage of chemicals and time<sup>19</sup>. Therefore, to bring such natural compounds into the drug discovery pipeline, computational approaches followed by advanced synthetic techniques lead to more significant benefits to improve the health and well-being with the help of next generation drugs<sup>6,20</sup>. In the current work *in-silico* method for target profiling is implemented for the identification of target proteins responsible for cancer and viral infections such as SARS-nCov-2 against anticancer and antiviral lipopeptides surfactin and iturin using web-based servers.

## Materials and Methods

### Pharmacophore Mapping using PharmMapper

Reverse pharmacophore mapping approach is used with the help of a web-based server PharmMapper. The studies are conducted for identification of target proteins for lipopeptide compounds with anticancer and antiviral properties<sup>4,21</sup>. The techniques have been previously utilized for the target proteins for essential oils of Cardomom and bis-pyrimidine compounds<sup>22</sup>. The PharmMapper server utilizes the reverse pharmacophore mapping to identify the potential targets for a given query compound. It utilizes an in-built database of pharmacophore models of 23,236 annotated proteins from targetBank, BindingDB, DrugBank, and Potential Drug Target Database (PDTD) with 51,431 ligandable and 16,159 druggable pharmacophore models. The server compares the query compound with models of the in-built database.

According to the similarity of the pharmacophore of the query compound with identified pharmacophore of the target proteins, the results are provided in the form of Zscore. Alongside the importance and indications of the identified protein in the disease are also provided<sup>23</sup>. Here the potential anticancer peptidolipidic compounds of *B. subtilis* are submitted as the query compound for possible target identification<sup>24</sup>. The selection of target proteins is done based on their importance in the cancer disease. The selected lipopeptides are reported with anticancer properties in literature.

The query compounds were submitted to PharmMapper server (<http://59.78.96.61/pharmmapper>). The PharmMapper server compares the pharmacophore of

the query compound with an in-built database of pharmacophore models. It predicts 300 target proteins based on their fitness score and pharmacophoric features. The target protein was ranked as per the fitness score and importance and indication of the protein. Generally, the top 10 proteins with a fitness score of more than 5 were considered to identify the probable target proteins of the query compound<sup>18</sup>.

#### **Swiss Target Prediction for target identification**

Swiss Target prediction is a web-based server developed by the Swiss Institute of Bioinformatics. This tool is used for the prediction of potential targets of a compound for which targets with Protein ID has not been explored. The website facilitates the estimation of probable targets of a query compound or a bioactive compound. The server has an in-built library of 370,000 known active compounds and more than 3000 target proteins from various species. In the updated version of the server, a large dataset on drug-protein interaction has been made available, which makes it a unique source of information. It is based upon a knowledge-based development approach for the identification of novel targets or secondary targets for uncharacterized compounds or known compounds, respectively. The server accurately predicts the targets for bioactive compounds based on two-dimensional and three-dimensional (2D and 3D) measures of similarity respective to the known compounds<sup>25-27</sup>.

Lipopeptides are known as potential anti-cancer, anti-viral compounds. However, the approach towards the identification of the target protein has not been explored. Hence, computational methods for pharmacophore mapping are utilised, which facilitate the identification of potential targets for lipopeptide-based drugs.

#### **Selection and retrieval of lipopeptides**

Lipopeptides with potent anticancer properties have been identified and screened through the rigorous literature survey. Surfactin and iturin have been chosen as the most prominent anticancer lipopeptides. The PubChem compound database is utilized to get the compound information. The canonical SMILES annotation of the query compounds were used to submit the molecules to the server and can be used to draw the compound into two-dimensional structure. The information were submitted into the servers in the form of canonical SMILES for query compounds.

#### **Pharmacophore mapping**

The two-dimensional structures of the above-mentioned lipopeptides were drawn using the information of canonical SMILES from the PubChem compound database., The 2D sketcher tool of Maestro suite (Schrodinger software package) was used to draw the structures. The server utilizes the sdf and mol2 (mole file formats/extensions for saving chemical structures) file formats for the submission of the query compound for pharmacophore mapping. Further, the individual structures were submitted to the software PharmMap-

per, which is a free web-based tool for the identification of target proteins based upon the structural complementarity with the submitted drugs. Results obtained through Pharmacophore mapping were further subjected to the structure prediction of the given proteins. Software is capable of providing a minimum of 10-300 target proteins based on their binding vicinity in which the drug should be able to dock and inhibit the target protein. The traditional sequence alignment methodology followed by structure prediction, and further data mining approaches were used for obtaining the three-dimensional structures of predicted proteins.

#### **Sequence alignment & structure prediction**

This step was performed using the retrieval of the FASTA sequence of each protein given in the mapping results. The FASTA sequence has further proceeded for sequence alignment using the Basic Local Alignment Search Tool abbreviated as BLAST, a web-based algorithm provided by the National Centre for Biotechnology Information (NCBI). On the basis of alignment score and keeping the query coverage in consideration, the higher similarity structures were retrieved from the Protein DataBank (PDB). The PDB structures were used as a template for the homology modeling of the FASTA sequence of the target proteins predicted through PharmMapper. Some of the FASTA sequences were traced with the 100% similarity in the sequence alignment. However, the experimental structures are available in the protein databank. Hence the structures can be retrieved for further studies.

#### **Target identification**

*In silico* target identification for drug molecules is the primary step in drug discovery, which includes various algorithms for the identification of genes and proteins. The availability of 3D structure of the target protein enables the identification of the best binding mode for understanding the interaction. Pharmacophore is a spatial arrangement of functional groups, is an essential core of the molecule which interacts with the receptor target molecule is the alternative method for deciphering molecular interaction.

#### **Multiple sequence alignment using T-Coffee server**

As per pharmacophore mapping results, the mapped protein with PDB ID 2R5K major capsid protein L1 of HPV (Human Papilloma Virus) (Table 1) was further subjected to multiple sequence alignment with SARS-nCoV-2 nucleocapsid protein. The FASTA sequences of both the proteins were retrieved from NCBI and submitted to the T-Coffee server, which uses Clustal\_W algorithm for multiple sequence alignment. Multiple sequence alignment is done to have an insight into the percentage similarity index between these two sequences. Sequence similarity searching helps in the identification of feasibility of drug repurposing for a given compound, as established antiviral drugs are repurposed to treat infection of SARS-nCoV-2 which is responsible for current COVID-19 pandemic.

Table 1. PharmMapper report for Surfactin: Depicting Hemoglobin subunit, multidrug-resistant operon, Major capsid viral protein and Histones as potential target class

PharmaMapper rank	PDB ID	Target name	Normalized fit score
+1	4YU4	None	0.9988
+2	3CKI	ADAM 17	0.9972
+3	1CG8	Hemoglobin subunit alpha	0.9957
+4	2HC5	Uncharacterized protein yvyc	0.9957
+5	1M15	Phosphoenolpyruvate phosphomutase	0.9944
+6	1NVM	4-hydroxy-2-oxovalerate aldolase	0.9925
+7	1HI5	Non-secretory ribonuclease	0.9908
+8	2OQC	Uncharacterized protein yxel	0.9774
+9	3ECH	Multidrug resistance operon repressor	0.9722
+10	1FB1	CREB-binding protein	0.9079
+72	2R5K	Major capsid protein L1	0.6073
+73	2CY3	Cytochrome C3-13 kDa	0.6067
	2NQB	Histone	0.6002

FASTA sequences of Major Capsid protein L1 of HPV:

>pdb|2R5H|D Chain D, Late Major Capsid Protein L1  
 AVVSTDEYVARTNIYYHAG-  
 TSRLLA VGHPYFPIKKNNN-  
 KILVPKVSGLQYRVFRIHLPDPNKFPGPDTS  
 FYNPDTQRLVWACVGVVEVGRGQPLGVGIS-  
 GHPLLNLDDTENASAYAANAGVDNRE-  
 CISMDYKQTQLCLI  
 GCKPPIGEHWGKGSPTQVAVQPGDCP-  
 PLELINTVIQDGMVDTGFGAMDFT-  
 TLQANKSEVPLDICTSIC  
 KYPDYIKMVSEPYGDSLFFYL-  
 RREQMFVRHLFNRAAGTVGEN-  
 VPDDLYIKGSGSTANLASSNYFPTPSGSM  
 VTSDAQIFNKPY  
 WLQRAQGHNNGICWGNQLFVTVVDTTRST  
 NMSLCAAISTSETTYKNTNFKEYLRHGEE  
 YDLQFIFQLCKITLTADVMTYIHSMNSTILED-  
 WNGGSGGEDPLKKYTFWEVNLKEKFSAD-  
 LDQFPLGRKF  
 LLQL

FASTA sequence of Nucleocapsid phosphoprotein of SARS-nCoV-2:

>QHR84456.1 nucleocapsid phosphoprotein [Severe acute respiratory syndrome coronavirus 2]  
 MSDNGPQNQRNAPRITFGG  
 PSDSTGSNQNGERSGARSKQRRPQGLPNNTASW  
 FTALTQHGKEDLKFPRGQ  
 GVPINTNSSPDDQIGYYRRATRRIRGG-  
 DGKMKDLSRWYFYLLGTGPEAGLPY  
 GANKDGIWVATEGALN  
 TPKDHIGTRNPANNAAL-  
 VLQLPQGTTLPKGFYAEGSRGGSQASSRSSRSR  
 NSSRNSTPGSSRGTSPTARM  
 AGNGGDAALALLLLDRLNQLESKMS  
 GKGGQQGQTVTKKSAAEASKKPRQKRTAT  
 KAYNVTQAFGRRGPE

QTQGNFGDQELIRQGTDYKHWQIAQFAPSAS-  
 AFFGMSRIGMEVTPSGTWLTYTGAI-  
 KLDDKDPNFKDQV  
 ILLNKHIDAYKTFPPTPEPKKDKKKKADETQAL-  
 PQRQKKQQTVTLL  
 PAADLDDFSKQLQQSMSSADSTQA

## Results and Discussion

### Prediction of target proteins for anticancer activities of lipopeptides

PharmMapper and Swiss Target Prediction predict the target proteins for a ligand molecule on the basis of the vicinity of the binding cavity of the target proteins, which can probably be inhibited through the query ligand molecule. The query ligand was used here is lipopeptide surfactin (Figure 2) for which the possible target proteins have been predicted and given in the table 1. According to the PharmMapper report depicted in (Table 1), hemoglobin subunits and membrane proteins have been predicted, which are associated with the hemolytic and surface active properties of surfactin, respectively<sup>28</sup>.

As per the PharmMapper results depicted in the (Table 1), top 10 ranked protein IDs are considered as the most significant target proteins. Resulting protein with PDB ID 4YU4 is a hemoglobin subunit that significantly proved to be associated with the hemolytic



Figure 2. 2D structure of cyclic lipopeptide-surfactin (query compound).

properties of the surfactin. As per the experimental studies, the hemolytic property is a hindrance of using surfactin as a potential anticancer compound. This was never been explored at the molecular level to understand the factors involved in the hemolytic property of the lipopeptide-based compounds<sup>29</sup>. Another protein with PDB ID predicted is 3CK1, a membrane protein which suggests the potential membrane affinity of the compound to lead its pore-forming activity as an antimicrobial compound. As FDA approved lipopeptide daptomycin is successfully used to treat the infections of multidrug-resistant bacteria<sup>30</sup>. To explore the anticancer activity of compounds, it is necessary to understand the interaction of the ligand at the target site. This study will give an insight into the lead optimization of the surfactin molecule to identify novel analogs with low or non-haemolytic property and higher affinity towards the target proteins for cancer and viral diseases. The studies would be a stepping stone towards the discovery of next-generation anti-cancer and antiviral compounds<sup>24,31,32</sup>.

As per Swiss Target Prediction report in figure 3 and table 2, major proteins predicted are from the apoptotic pathway, which is having significant role in the cancer progression. Inhibition of such a signaling pathway plays a major role in cell death, which has been explained in the mechanism of action of anti-

cancer lipopeptides that they induce the cell cycle arrest and leads to cell death<sup>33</sup>. The predicted proteins can be further explored with the help of structural bioinformatics and computer-aided drug designing studies. The work can be extended further for lead optimization studies for a given class of drugs to design a molecule with better efficiency and specificity to inhibit a particular target protein<sup>7,34</sup>.

The Swiss Target Prediction report in figure 3 is depicting the surfactin structure as a query compound, and a pie chart is depicting the percentage mapping with the target class. The results show surfactin as a potential ligand for major proteases (60%), adhesins, and membrane receptors. Lipopeptides being amphiphilic compounds are found with membrane affinity properties, which can be proved with these results<sup>35,36</sup>. Tables 2 and 3 suggest the Caspase proteins as the potential class of target proteins for surfactin. Caspases have a significant role in cancer progression<sup>37</sup>. Being a potential target of peptide therapeutics, this aspect can be explored in conjunction with inhibitory/catalytic activity to regularize the class of caspase proteins in cancer management<sup>10,37</sup>.

Swiss Target Prediction report generated against lipopeptide iturin reveals the G-Protein Coupled Receptors (GPCR) as the most prominent class of targets for iturin (Figure 4 and Table 4). Drugs targeting GPCR's are used to treat many diseases. More than 40% FDA approved drugs are aimed to target GPCR's and their related pathways. Now, GPCR's are being used as biomarkers for early diagnosis of cancer, as they play critical role in activating and regulating signaling pathways associated to cancer<sup>38</sup>. Hence, iturin would be a promising compound to be explored to develop as potential anticancer drug<sup>38</sup>.

#### Prediction of viral targets for antiviral activity of lipopeptides

Pharmacophore mapping studies suggested various viral targets along with the anticancer studies. The




Figure 3. Swiss Target prediction query structure for Surfactin and prediction report with percentage affinity with class of target protein.

Table 2. Surfactin Swiss Target Prediction report depicting Caspases, Proteases and Membrane receptor proteins as potential targets classes and deciphering Angiotensin Converting enzyme (ACE2) as potential target against SARS-nCoV-2 under top 50 targets aligned

Target	Common name	Uniprot ID	ChEMBL ID	Target class
Caspase-2	CASP2	P42575	CHEMBL4884	Protease
Caspase-3	CASP3	P42574	CHEMBL2334	Protease
Caspase-8	CASP8	Q14790	CHEMBL3776	Protease
Caspase-1	CASP1	P29466	CHEMBL4801	Protease
Proteasome macropain subunit MB1	PSMB5	P28074	CHEMBL4662	Protease
P-selectin	SELP	P16109	CHEMBL5378	Adhesion
Integrin alpha-V/beta-3	ITGAV ITGB3	P06756 P05106	CHEMBL1907598	Membrane receptor
Caspase-7	CASP7	P55210	CHEMBL3468	Protease
Cathepsin D	CTSD	P07339	CHEMBL2581	Protease
Thrombin	F2	P00734	CHEMBL204	Protease
Selectin E	SELE	P16581	CHEMBL3890	Adhesion
Leucocyte adhesion molecule-1	SELL	P14151	CHEMBL4198	Adhesion
Angiotensin-converting enzyme	ACE	P12821	CHEMBL1808	Protease

Table 3. SwissTarget Prediction report for Surfactin

Target	Uniprot ID	Gene code	ChEMBL ID	Probability	#sim. cmpds (3D/2D)	Target class
Caspase-3 subunit p12	P42574	CASP3	CHEMBL2334		3/112	Cysteine protease
Caspase-7 subunit p20	P55210	CASP7	CHEMBL3468		3/111	Cysteine protease
Caspase-6 subunit p18 (by homology)	P55212	CASP6	CHEMBL3308		3/112	Cysteine protease
Caspase-1 subunit p20	P29466	CASP1	CHEMBL4801		6/147	Cysteine protease
Caspase-4 (by homology)	P49662	CASP4	CHEMBL2226		6/147	Cysteine protease
Caspase-5 subunit p10 (by homology)	P51878	CASP5	CHEMBL3131		6/147	Cysteine protease
Inactive caspase-12 (by homology)	Q6UXS9	CASP12			6/147	Cysteine protease
Caspase-8 subunit p18	Q14790	CASP8	CHEMBL3776		3/67	Cysteine protease
Complex	P06756/P05106	ITGAV/ITGB3	CHEMBL1907598		13/87	Membrane receptor
Complex	P08514/P05106	ITGA2B/ITGB3	CHEMBL2093869		1/138	Membrane receptor
Renin	P00797	REN	CHEMBL286		5/459	Aspartic protease
Cathepsin D	P07339	CTSD	CHEMBL2581		5/454	Aspartic protease
Napsin-A (by homology)	O96009	NAPSA			5/454	Aspartic protease
Uncharacterized protein (by homology)	H7C469				1/88	Aspartic protease
Caspase-2 subunit p18	P42575	CASP2	CHEMBL4884		0/18	Cysteine protease




Figure 4. Iturin as query molecule for Swiss Target Prediction with prediction report in percentage for target class.

studies contain significant findings for the identification of next-generation antiviral drugs to combat the diseases like COVID-19. As per table 1 multidrug resistance operon repressor is found as a predicted target, which suggests the proven antibiotic activity against multidrug resistance strains <sup>6</sup>. Table 4 depicts the Angiotensin-Converting Enzyme (ACE) as one of the potential targets of iturin. The affinity of a compound towards ACE2 is significant as Human-ACE2 is a potential target for SARS-nCov-2 Spike-glycoprotein. Inhibition of such interaction plays a vital role in the treatment of Corona virus disease (COVID-19) <sup>9</sup>. The findings from table 1 generated through PharmMapper results for surfactin, suggested the affinity towards major capsid protein of Human Papilloma virus (PDB ID: 2R5K). Clustal\_W analysis results gave approximately 21% similarity with SARS-nCoV-2 nucleocapsid protein. The results suggest the drug repurposing opportunity with the identification of a similar category of drugs with a high affinity towards

SARS-nCoV-2 viral proteins <sup>15,39</sup>. Table 4 is also suggesting affinity towards a viral protein Baculoviral IAP repeat-containing protein <sup>40</sup>.

## Conclusion

Synergistically conducted studies on target protein identification of microbial peptidolipidic compounds give more promising and reliable results regarding the target class of compounds. The experimental studies were touched at the level of mechanistic action but could not lead towards optimization and novel analog designing, which required the structural and molecular information of drug and target protein. Through the *in silico* studies, the multitargeting efficiency of lipopeptide compounds is depicted, which is not feasible with a small molecule inhibitor. This suggests the higher specificity and efficiency in binding with the target site. In the current studies, antiviral and anticancer properties of lipopeptide compounds have given various horizons for future perspectives in developing next-generation novel compounds. It is the need of the hour to explore novel compounds to combat future infectious diseases like COVID-19 pandemic and deadly cancer diseases. The study concludes various classes of potential viral targets and cancer target proteins to facilitate the drug discovery process with the possible targets and ligands to study the interaction and discover the promising drug candidates. Utilization of microbial bi-products is much feasible than producing peptide therapeutics in the laboratory, which incurs huge chemical exposure and a financial burden as well with the wastage of chemicals, time and money. Rather computational prediction eases out the journey to some ex-

## Modern Paradigm Towards Potential Target Identification for Antiviral (SARS-nCoV-2) and Anticancer Lipopeptides

Table 4. Swiss Target Report (prediction of GPCR's, Caspases and ACE as targets for Iturin) and predicted Cyclin dependent kinases (CDK's) through mapping against Iturin

Target	Common name	Uniprot ID	ChEMBL ID	Target class
Acetylcholine receptor protein delta chain	CHRND	Q07001	CHEMBL3011	Ligand-gated ion channel
Acidic mammalian chitinase	CHIA	Q9BZP6	CHEMBL1293197	Enzyme
Acyl-CoA: Dihydroxyacetonephosphateacyltransferase	GNPAT	O15228	CHEMBL4494	Enzyme
Angiotensin-converting enzyme	ACE	P12821	CHEMBL1808	Protease
Apetite regulating hormone	GHRL	Q9UBU3	CHEMBL1921664	Unclassified protein
Baculoviral IAP repeat-containing protein 3	BIRC3	Q13489	CHEMBL5335	Enzyme
Beta secretase 2	BACE2	Q9Y5Z0	CHEMBL2525	Protease
Beta secretase 1	BACE1	P56817	CHEMBL4822	Protease
C-X-C chemokine receptor type 7	ACKR3	P25106	CHEMBL2010631	Family A G-protein coupled receptor
Calcitonin gene-related peptide type 1 receptor	CALCRL	Q16602	CHEMBL3798	Family B G-protein coupled receptor
Carboxypeptidase B2 isoform A	CPB2	Q96Y4	CHEMBL3419	Protease
Carboxypeptidase N catalytic subunit	CPN1	P15169	CHEMBL4713	Protease
Caspase-1	CASP1	P29466	CHEMBL4801	Protease
Caspase-2	CASP2	P42575	CHEMBL4884	Protease
Cyclin-dependent kinase 4/cyclin D1	CCND1 CDK4	P24385 P11802	CHEMBL1907601	Kinase
CDK2/Cyclin A CCNA2	CDK2	P20248 P24941	CHEMBL3038469	Kinase
Histone deacetylase 8	HDAC8	Q9BY41	CHEMBL3192	Eraser
Chymotrypsin C	CTRC	Q99895	CHEMBL2386	Protease
Signal transducer and activator of transcription 6	STAT6	P42226	CHEMBL5401	Transcription factor
Melanocortin receptor 5	MC5R	P33032	CHEMBL4608	Family A G-protein coupled receptor
E3 SUMO-protein ligase	CBX4	O00257	CHEMBL3232685	Enzyme
Ceramide glucosyltransferase	UGCG	Q16739	CHEMBL2063	Family A G-protein coupled receptor
Neurokinin 1 receptor	TACR1	P25103	CHEMBL249	Family A G-protein coupled receptor
Cholecystokinin B receptor	CCKBR	P32239	CHEMBL298	Family A G-protein coupled receptor
Interleukin-1 beta	IL1B	P01584	CHEMBL1909490	Secreted protein
Proteinase-activated receptor 1	F2R	P25116	CHEMBL3974	Family A G-protein coupled receptor

tent. It gives a better understanding of the drug-target interaction at the molecular level. The research can be further explored with molecular dynamics studies for a more in-depth understanding of lead optimization and exploring these compounds with more potency and least side effects.

### Acknowledgement

We are thankful to the National Institute of Technology Raipur and Chhattisgarh Council of Science and Technology (CCOST) (Project number 2487/CCOST/MRP/2016, Raipur dated 25.01.2016), India for providing the necessary facilities to prepare the manuscript and permission to publish it.

### Conflict of Interest

The authors declare no conflict of interest.

### Ethical Approval

This article does not contain any studies with human participants or animals performed by any of the authors.

### References

1. Bruno A, Costantino G, Sartori L, Radi M. The in silico drug discovery toolbox: applications in lead discovery and optimization. *Curr Med Chem* 2019;26(21):3838-73.
2. Sauna ZE, Lagassé HAD, Alexaki A, Simhadri VL, Katagiri NH, Jankowski W, et al. Recent advances in (therapeutic protein) drug development. *F1000Res* 2017;6: 113.
3. Neu HC. The crisis in antibiotic resistance. *Science* 1992;257(5073):1064-73.
4. Meena KR, Kanwar SS. Lipopeptides as the Antifungal and antibacterial agents: applications in food safety and therapeutics. *Biomed Res Int* 2015;2015:473050.
5. Caulier S, Nannan C, Gillis A, Licciardi F, Bragard C, Mahillon J. Overview of the antimicrobial compounds produced by members of the *Bacillus subtilis* group. *Front Microbiol* 2019;10:302.
6. Cochrane SA, Vederas JC. Lipopeptides from *Bacillus* and *Paenibacillus* spp.: A gold mine of antibiotic candidates. *Med Res Rev* 2016;36(1):4-31.
7. Jujavarapu SE, Dhagat S, Yadav M. Computer-Aided Design of Antimicrobial Lipopeptides As Prospective

- Drug Candidates. CRC Press LLC; 2019. 146 p.
8. Pham JV, Yilma MA, Feliz A, Majid MT, Maffetone N, Walker JR, et al. A review of the microbial production of bioactive natural products and biologics. *Front Microbiol* 2019;10:1404.
  9. Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. *Cell Res* 2020;30(4):343-55.
  10. Lau JL, Dunn MK. Therapeutic peptides: Historical perspectives, current development trends, and future directions. *Bioorganic Med Chem* 2018;26(10):2700-7.
  11. Craik DJ, Fairlie DP, Liras S, Price D. The future of peptide-based drugs. *Chem Biol Drug Des* 2013;81:136-47.
  12. Yadav M, Dhagat S, Eswari JS. Emerging strategies on in silico drug development against COVID-19: challenges and opportunities. *Eur J Pharm Sci* 2020;155:105522.
  13. Chowdhury T, Baindara P, Mandal SM. LPD-12: a promising lipopeptide to control COVID-19. *Int J Antimicrob Agents* 2021;57(1):106218.
  14. de Vries RD, Schmitz KS, Bovier FT, Predella C, Khao J, Noack D, et al. Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets. *Science* 2021;371(6536):1379-82.
  15. Chartier M, Najmanovich R. Detection of binding site molecular interaction field similarities. *J Chem Inf Model* 2015;55(8):1600-15.
  16. Ciemny M, Kurcinski M, Kamel K, Kolinski A, Alam N, Schueler-Furman O, et al. Protein-peptide docking: opportunities and challenges. *Drug Discov Today* 2018;23(8):1530-7.
  17. Liu X, Ouyang S, Yu B, Liu Y, Huang K, Gong J, et al. PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach. *Nucleic Acids Res* 2010;38 (Web Server issue):W609-14.
  18. Meshram RJ, Baladhya VB, Gacche RN, Karale BK, Gaikar RB. Pharmacophore mapping approach for drug target identification: a chemical synthesis and in silico study on novel thiazole compounds. *J Clin Diagn Res* 2017;11(5):KF01-KF08.
  19. Mojsoska B, Jenssen H. Peptides and peptidomimetics for antimicrobial drug design. *Pharmaceuticals (Basel)* 2015;8(3):366-415.
  20. Sable R, Parajuli P, Jois S. Peptides, peptidomimetics, and polypeptides from marine sources: A wealth of natural sources for pharmaceutical applications. *Mar Drugs* 2017;15(4):124.
  21. Kumar S, Singh J, Narasimhan B, Shah SAA, Lim SM, Ramasamy K, et al. Reverse pharmacophore mapping and molecular docking studies for discovery of GTPase HRas as promising drug target for bis-pyrimidine derivatives. *Chem Cent J* 2018;12(1):106.
  22. Bhattacharjee B, Chatterjee J. Identification of proapoptotic, anti-inflammatory, anti-proliferative, anti-invasive and anti-angiogenic targets of essential oils in cardamom by dual reverse virtual screening and binding pose analysis. *Asian Pac J Cancer Prev* 2013;14(6):3735-42.
  23. Meshram RJ, Baladhya VB, Gacche RN, Karale BK, Gaikar RB. Pharmacophore mapping approach for drug target identification: A chemical synthesis and in silico study on novel thiazole compounds. *J Clin Diagn Res* 2017;11(5):KF01-KF08.
  24. Seydlová G, Svobodová J. Review of surfactin chemical properties and the potential biomedical applications. *Cent Eur J Med* 2008;123-33.
  25. SwissTargetPrediction: A Web Server for Target Prediction of Bioactive Small Molecules - PubMed [Internet]. [cited 2020 Jul 10]. Available from: <https://pubmed.ncbi.nlm.nih.gov/24792161/>
  26. Gfeller D, Grosdidier A, Wirth M, Daina A, Michielin O, Zoete V. SwissTargetPrediction: A web server for target prediction of bioactive small molecules. *Nucleic Acids Res* 2014;42(Web Server issue):W32-8.
  27. Daina A, Michielin O, Zoete V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. *Nucleic Acids Res* 2019;47(W1):W357-364.
  28. Inès M, Dhouha G. Lipopeptide surfactants: Production, recovery and pore forming capacity. *Peptides* 2015 Sep; 71:100-12.
  29. Kracht M, Rokos H, Özel M, Kowall M, Pauli G, Vater J. Antiviral and hemolytic activities of surfactin isoforms and their methyl ester derivatives. *J Antibiot (Tokyo)* 1999;52(7):613-9.
  30. Kopp F, Marahiel MA. Macrocyclization strategies in polyketide and nonribosomal peptide biosynthesis. *Nat Prod Rep* 2007;24(4):735-49.
  31. Lavecchia A, Giovanni C. Virtual screening strategies in drug discovery: A critical review. *Curr Med Chem* 2013; 20(23):2839-60.
  32. Rishon GM. Nonleadlikeness and leadlikeness in biochemical screening. *Drug Discov Today* 2003;8(2):86-96.
  33. Wu YS, Ngai SC, Goh BH, Chan KG, Lee LH, Chuah LH. Anticancer activities of surfactin potential application of nanotechnology assisted surfactin delivery. *Front Pharmacol* 2017;8:761.
  34. Katsila T, Spyroulias GA, Patrinos GP, Matsoukas MT. Computational approaches in target identification and drug discovery. *Comput Struct Biotechnol J* 2016;14: 177-84.
  35. Maget-Dana R, Thimon L, Peypoux F, Ptak M. Surfactin/iturin A interactions may explain the synergistic effect of surfactin on the biological properties of iturin A. *Biochimie* 1992;74(12):1047-51.
  36. Maget-Dana R, Peypoux F. Iturins, a special class of pore-forming lipopeptides: biological and physicochemical properties. *Toxicology* 1994;87(1-3):151-74.
  37. Clark A, MacKenzie S. Targeting cell death in tumors by activating caspases. *Curr Cancer Drug Targets* 2008;8(2):98-109.

38. Yu S, Sun L, Jiao Y, Lee LTO. The role of G protein-coupled receptor kinases in cancer. *Int J Biol Sci* 2018; 14(2):189-203.
39. Demirbař A, Eker H, Elmas ÖF, Ulutař Demirbař G, Atasoy M, Türsen Ü, et al. COVID-19 and human papillomavirus: Paradoxical immunity. *J Cosmet Dermatol* 2021;20(7):2001-3.
40. Wang J. New strategy for COVID-19 vaccination: targeting the receptor-binding domain of the SARS-CoV-2 spike protein *Cell Mol Immunol* 2021 Feb;18(2):243-44.